Dr. Howard Fillit & Mark Roithmayr of ADDF on Alzheimer’s Innovation, Funding & Biomarkers

Synopsis: What happens when a world-class scientist and a philanthropic legacy collide with one of medicine’s greatest challenges? Dr. Howard Fillit and Mark Roithmayr of the Alzheimer’s Drug Discovery Foundation (ADDF) join host Alok Tayi for an inspiring conversation on bold science, visionary funding models, and the future of Alzheimer’s research. From treating Estée Lauder in the 1990s to building a $100M venture philanthropy engine, they trace ADDF’s evolution into a global leader in high-risk, high-reward drug development. The discussion covers the rise of biomarkers and digital diagnostics, the foundation’s partnerships with visionaries like Bill Gates and Jeff Bezos, and how ADDF’s venture philanthropy approach bridges the “valley of death” in biotech. They also dive into global regulatory challenges, the economic urgency of Alzheimer’s, and why the future lies in prevention, precision medicine, and a patient-first mindset. This episode is a masterclass in scientific grit, ecosystem thinking, and turning urgency into progress. Biography: Howard Fillit, MD Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation Howard Fillit, MD, is a geriatrician, neuroscientist, and innovative philanthropy executive, who has led the Alzheimer’s Drug Discovery Foundation (ADDF) since its founding. Dr. Fillit has held faculty positions at The Rockefeller University, the SUNY-Stony Brook School of Medicine and the Cornell University School of Medicine. In 1987, he joined the Mount Sinai School of Medicine, where he is a clinical professor of geriatric medicine and palliative care, medicine and neuroscience. Dr. Fillit also maintains a limited private practice in consultative geriatric medicine with a focus on Alzheimer's disease and related dementias. He has authored or co-authored more than 300 publications and is the senior editor of Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Dr. Fillit is the recipient of many awards and honors including the Rita Hayworth Award from the Alzheimer's Association. Mark Roithmayr Chief Executive Officer Mark Roithmayr is an admired nonprofit leader with four decades of experience in both start-ups and mature organizations. As CEO of the ADDF, he is responsible for steering the Foundation’s overall strategy, focus, and business operations. Since joining the ADDF in 2017, the organization has transformed dramatically in impact, scale, presence, and brand. Under his leadership, the ADDF’s revenue has increased five-fold from $17M to over $90M, and mission-related investing has grown over 100%. He works closely with Dr. Fillit, executive leadership, and the board to advance the ADDF’s mission of accelerating the discovery of drugs to prevent, treat, and cure Alzheimer’s disease and related dementias. His key accomplishments include securing donations from Bill Gates, Jeff Bezos, and MacKenzie Scott, and a 10-figure gift from the Lauder family to cover ADDF’s overhead for the next 20 years.